Chief Financial Officer · Lineage Cell Therapeutics, Inc. (LCTX)

Kevin Cook

FY2021 is the first fiscal year CompBrief holds for Kevin Cook as a named executive officer of Lineage Cell Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2021

$1,660,209

Salary $214,773Stock awards $0Bonus $101,200

2nd of 3 named executive officers at Lineage Cell Therapeutics by FY2021 total.

3 named officers on file for Lineage Cell Therapeutics, FY2021

Kevin Cook’s pay file — $29

  • 1 fiscal year of pay, line by line
  • 1 equity grant, each cited to its filing
  • LCTX’s disclosed peer group of 22 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Lineage Cell Therapeutics’s whole pay program stands against its peers

  • Lineage Cell Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on LCTX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2022 (DEF 14A).

Free

Get Kevin Cook’s full pay file as a PDF — free

More than this page: up to 10 years of Kevin’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Kevin Cook compensation by year

Lineage Cell Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as Lineage Cell Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021
Salary$214,773
Bonus$101,200
Stock awards$0
Option awards$1,316,550
Non-equity incentive$0
Pension and deferred compensation$0
All other$27,686
Total$1,660,209

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Lineage Cell Therapeutics, Inc. DEF 14A filed April 29, 2022, accession 0001493152-22-011552, and prior-year filings.

How this page was built: the Lineage Cell Therapeutics, Inc. filed document, accession 0001493152-22-011552. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2022.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
Option750,000—$2.68

Per the Outstanding Equity Awards at Fiscal Year-End table in Lineage Cell Therapeutics, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Lineage Cell Therapeutics’s named executive officers, FY2021

as the company reported each
Named executive officerRoleFY2021 total
Brian CulleyChief Executive Officer$2,754,475
Kevin Cook · this pageChief Financial Officer$1,660,209
George Samuel IIIGeneral Counsel and Corporate Secretary$1,330,376

The full Lineage Cell Therapeutics compensation record

free company brief

This page is one person within Lineage Cell Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Lineage Cell Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Lineage Cell Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Kevin Cook's compensation dossier · One-time report. No refunds.